Directory Category: Drug Discovery

Medicines Discovery Catapult (MDC) and SMi have secured a Biomedical Catalyst (BMC) grant to validate a new approach to detect cancer biomarkers. It will transform their use for routine cancer screening and enable monitoring of...

CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen ADCs directed against up to two targets. Immunosynthen, Mersanaís proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both ​tumor-resident immune cells and in antigen-expressing tumor cells, unlocking the anti-tumor potential of innate immune stimulation.​

London, United Kingdom, 6th December 2022 / Sciad Newswire / MultiOmic Health, an artificial intelligence-enabled precision medicine discovery company, today announces the signing of a research collaboration agreement with...

Oxford, UK, 16 November 2022: The Native Antigen Company (part of
LGC Clinical Diagnostics), one of the worldís leading suppliers of
reagents that enables research into vaccines and diagnostics for
emerging and endemic infectious diseases, today announced the commercial
launch of its latest range of influenza antigens for the southern
hemisphereís 2023 flu season. The latest influenza antigens will help
support development of vaccines and diagnostics as part of the ongoing
vaccine reformulation programme, helping to ensure public safety
throughout the annual flu season.